🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong. Could this combo help overcome resistance in more aggressive ALK variants? Oscar Arrieta

Yvonne Diaz Oscar Arrieta ALK Positive Australia Inc. Oncogene Cancer Research Jordi Remon Instituto Nacional de Cancerología Luis Lara-Mejía Instituto Oncológico Dr Rosell Pangaea Oncology We’re encouraged by new treatment options like this combo showing strong responses & prolonged progression-free survival. Improved brain control is especially important to us. We look forward to more research that offers hope and better quality of life for ALK+ patients worldwide

Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib ascopubs.org/doi/10.1200/PO…

Great to see ctDNA NGS is now fully funded by NHS England for routine blood draw at presentation of advanced #NSCLC to clinic or as emergency admission tinyurl.com/ykd2bn96 Now we need max implementation for max benefit! BTOG British Thoracic Society (BTS) Lung Cancer Nursing UK

What a guy. I would’ve done anything to save you, Dad 💔🤍 m.sweeneymemorialfh.com/obituaries/eve… #lcsm #lungcancer #egfr

For US colleagues, the Isle of Wight is like Nantucket, but better. UCLH Charity EGFR Positive Lung Cancer UK EGFR Resisters

Phase 3 #HERTHENA-Lung02 study: ▫️HER3-DXd v chemo in EGFRm NSCLC post 3G TKI ▫️mPFS: 5.8 v 5.4 mo (HR 0.77) ▫️ORR: 35% v 25% ▫️🧠PFS: 5.4 v 4.2 mo (HR 0.75) ▫️TEAEs G≥3: 73% v 57%, mostly thrombocytopenia ▫️5% ILD (w/ 2 G5 events) #ASCO25 EGFR Resisters OncoAlert

Young people get #cancer. Amy was just 20 when she was diagnosed w stage 4 #lungcancer. Her story & others show why we must act now. Amy’s what’s inspired Janclark to co-found our charity. Thanks The Sun for covering this important issue: thesun.co.uk/health/3502801… 🩵 #LCSM

If you’re reading this and will be at #ASCO25 pop over to say hello and we can chat all things ALK ASCO OncoAlert

Sunday marks the start of ALK Positive Awareness Month, but Mike Gielow isn't waiting. On Saturday, he's kicking off #APAM w a fundraiser for research & veteran support. This is what #PoweredByPatients looks like. Help him reach his $10k goal: secure.qgiv.com/event/alkposit…

We’re heading to #ASCO25! Our team will meet with researchers, pharma & biotech partners to advance outcomes for the ALK+ community. We’re also hosting our Scientific Advisory Board & connecting with advocacy orgs. Progress happens when we work together. #PoweredByPatients

Looking forward to #ASCO25. Fortunate to be a part of this amazing @alkpositiveinc crew and flying the flag for our UK charity @oncogenecancer (set up w @janclarkgirls).

🚨 BREAKING: HARMONi Trial Results Ivonescimab + chemo delivers a significant PFS benefit in EGFR-mutant NSCLC after EGFR TKI failure! 📊 PFS HR: 0.52 (p < 0.00001) 🧬 OS trending positive: HR 0.79 (p = 0.057)- not mature. 🌍 Global study with 38% Western pts 🛡 Manageable

What if a blood test could find #lungcancer before symptoms appear? NHS England is rolling out the EarlyCDT-Lung test—giving more people the chance to catch cancer early, when it can still be treated and hope is strongest. england.nhs.uk/2025/05/nhs-fi… #ASCO25 #LCSM

Remarkable results in pretreated EGFR mutant lung cancer! In global trial, stellar benefit in progression-free survival for the addition of ivonescimab to platinum doublet chemo. Given tox profile may be a preferred option in this setting. #LCSM #ASCO25

Best #ASCO25 exhibit hall food part 1: right (near posters) and middle of room. Eat up!

More of my favorite people from yesterday Jill Feldman EGFR Resisters Yvonne Diaz Oncogene Cancer Research ALK Positive Upal LUNGevity Foundation Stacey Tinianov (she/her) MPH, BCPA Barry Stein Colorectal Cancer Canada Team #CANCAN Cancer Grand Challenges

.Marcelo Corassa, MD. beautifully discusses EGFR/HER2 ex20ins development. Puts zipalertib data in context: similar ORRs. Tox of amivantamab is difficult & better for zipa. Suggests start with TKI and move to ami 2nd. In HER2, AE profile suggests TKI 1st may be preferable #ASCO25

📍Full house today at the Patient Advocate Lounge with key panelists discussing the key contributions of #patientadvocates to Oncology research & care. 📍A good reminder that at the end of the day, patients & advocates are the most important people in the room #ASCO25 #HearHer

.Charlie Rudin Dellpi304 RP3 Tarla vs chemo-mono in 2L ES-SCLC Asymptomatic untreated CNS mets allowed. 44% plat resitnt 1o: OS PFS HR 0.61: 3.7 vs 4.2 mo; tail developing OS HR 0.6 at IA1 13.6 vs 8.3mo ORR: 35 vs 20% DOR: 6.9 vs 5.5 Nil new re AEs A new SOC #ASCO25